No Data
Neptune Biology: 2024 Annual Report
Neptune Biotech: Report for the first quarter of 2025
Neptune Biology: 2024 Annual Report Summary
Shenzhen Neptunus Bioengineering (000078.SZ): In the first quarter, the Net income was 23.7158 million yuan, a year-on-year decrease of 44.38%.
Gelonghui, on April 28, reported that Shenzhen Neptunus Bioengineering (000078.SZ) announced its first quarter report, with revenue of 7.376 billion yuan, a year-on-year decrease of 8.81%. The net income attributable to shareholders of the listed company was 23.7158 million yuan, a year-on-year decrease of 44.38%, and the non-recurring net loss was 74.74 million yuan.
There's No Escaping Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Muted Revenues
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Further Weakness as Shenzhen Neptunus Bioengineering (SZSE:000078) Drops 5.4% This Week, Taking Five-year Losses to 46%
